Table 2.

Demographic, periodontal and bacterial variables of CsA-treated patients in GO+ and GO− groups

	GO+(n=124)	GO−(n=80)	p-value
Age(years)	45.0±10.1	45.0±12.2	0.98
Gender distribution(F:M)	40:84	32:48	0.26
Duration of CsA therapy (years)	4.2±4.0	4.1±4.6	0.74
CsA dosage(mg/day)	190±48	189±46	0.84
CsA serum concentration(μg/l)	705±233	764±269	0.10
Calcium channel blocker use (%)	64(52%)	36(45%)	0.36
PLI	1.44±0.65	0.58±0.41	<0.001
PBI	1.21±0.75	0.42±0.36	<0.001
PD(mm)	3.44±0.87	1.90±0.49	<0.001
Pg	106(85.5)	45(56.3)	<0.001
Aa	92(74.2)	57(71.3)	0.747
Pi	72(58.1)	36(45.0)	0.085
Td	108(87.1)	43(53.8)	<0.001
Tf	97(78.2)	49(61.3)	0.011
Pg+ Td+ Tf	81(65.3)	20(25.0)	<0.001

Bold represents a significant difference (p<0.05).

CsA, cyclosporine A; GO, gingival overgrowth; PLI, plaque index; PBI, papillary bleeding index; PD, probing depth; Pg, Porphyromonas gingivalis; Aa, Aggregatibacter actinomycetemcomitans; Pi, Prevotella intermedia; Td, Treponema denticola; Tf, Tannerella forsythia.